Martinez Flores, D.; Akhoundova, D.; Seipel, K.; Legros, M.; Kronig, M.-N.; Daskalakis, M.; Bacher, U.; Pabst, T.
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia. Biomedicines 2024, 12, 1616.
https://doi.org/10.3390/biomedicines12071616
AMA Style
Martinez Flores D, Akhoundova D, Seipel K, Legros M, Kronig M-N, Daskalakis M, Bacher U, Pabst T.
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia. Biomedicines. 2024; 12(7):1616.
https://doi.org/10.3390/biomedicines12071616
Chicago/Turabian Style
Martinez Flores, Danaë, Dilara Akhoundova, Katja Seipel, Myriam Legros, Marie-Noelle Kronig, Michael Daskalakis, Ulrike Bacher, and Thomas Pabst.
2024. "Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia" Biomedicines 12, no. 7: 1616.
https://doi.org/10.3390/biomedicines12071616
APA Style
Martinez Flores, D., Akhoundova, D., Seipel, K., Legros, M., Kronig, M.-N., Daskalakis, M., Bacher, U., & Pabst, T.
(2024). Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia. Biomedicines, 12(7), 1616.
https://doi.org/10.3390/biomedicines12071616
